NCT02380573View on ClinicalTrials.gov

Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

April 21, 2022

Study Completion Date

July 31, 2023

Conditions
Mild Cognitive ImpairmentMCIAgingAlzheimer's DiseaseAD
Interventions
DRUG

Methylene Blue

DRUG

FD&C Blue # 2

DRUG

Phenazopyridine hydrochloride

Trial Locations (1)

78229

Research Imaging Institute, The University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

Texas Alzheimer's Research and Care Consortium

OTHER

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT02380573 - Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease | Biotech Hunter | Biotech Hunter